Also trades as: TOIIW (NASDAQ) · $vol 0M
TOI NASDAQ
The Oncology Institute, Inc.
1W: +10.6%
1M: +29.9%
3M: +74.6%
YTD: +21.8%
1Y: +60.8%
3Y: +932.3%
5Y: -55.3%
$4.59
+0.12 (+2.68%)
Weekly Expected Move ±7.9%
$3
$4
$4
$4
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$503M
+27.8% ▲
5Y CAGR: +21.8%
Gross Profit
$69M
+28.7% ▲
5Y CAGR: +13.5%
Operating Income
-$36M
+40.0% ▲
Net Income
-$61M
+6.3% ▲
EPS (Diluted)
$-0.54
+23.9% ▲
EBITDA
-$29M
+45.9% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $203M | $252M | $324M | $393M | $503M |
| YoY Growth | +8.3% | +24.4% | +28.4% | +21.3% | +27.8% |
| Cost of Revenue | $162M | $200M | $265M | $339M | $433M |
| Gross Profit | $41M | $52M | $60M | $54M | $69M |
| Gross Margin | 20.1% | 20.6% | 18.4% | 13.7% | 13.8% |
| R&D Expenses | $0 | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 | $106M |
| Operating Expenses | $87M | $134M | $137M | $114M | $106M |
| Operating Income | -$46M | -$82M | -$77M | -$60M | -$36M |
| Operating Margin | -22.6% | -32.5% | -23.8% | -15.3% | -7.2% |
| Interest Expense | $320K | $4M | $7M | $7M | $11M |
| Income Before Tax | -$12M | -$91K | -$83M | -$65M | -$61M |
| Tax Expense | -$671K | -$243K | -$36K | $0 | -$131K |
| Net Income | -$11M | $152K | -$83M | -$65M | -$61M |
| Net Margin | -5.4% | 0.1% | -25.6% | -16.4% | -12.1% |
| EPS (Diluted) | $-0.16 | $-0.21 | $-0.92 | $-0.71 | $-0.54 |
| EBITDA | -$42M | -$68M | -$54M | -$54M | -$29M |
| Shares Outstanding | 66M | 81M | 74M | 75M | 924M |